company background image
2RZ logo

Poseida Therapeutics DB:2RZ Stock Report

Last Price

€2.25

Market Cap

€219.4m

7D

-1.7%

1Y

11.3%

Updated

11 Oct, 2024

Data

Company Financials +

Poseida Therapeutics, Inc.

DB:2RZ Stock Report

Market Cap: €219.4m

Poseida Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poseida Therapeutics
Historical stock prices
Current Share PriceUS$2.25
52 Week HighUS$3.82
52 Week LowUS$1.71
Beta0.51
11 Month Change-15.04%
3 Month Change-26.15%
1 Year Change11.29%
33 Year Change-58.75%
5 Year Changen/a
Change since IPO-80.60%

Recent News & Updates

Recent updates

Shareholder Returns

2RZDE BiotechsDE Market
7D-1.7%-1.0%0.6%
1Y11.3%-13.8%11.8%

Return vs Industry: 2RZ exceeded the German Biotechs industry which returned -13.8% over the past year.

Return vs Market: 2RZ matched the German Market which returned 11.8% over the past year.

Price Volatility

Is 2RZ's price volatile compared to industry and market?
2RZ volatility
2RZ Average Weekly Movement10.6%
Biotechs Industry Average Movement6.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2RZ's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2RZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2014337Kristin Yaremaposeida.com

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.

Poseida Therapeutics, Inc. Fundamentals Summary

How do Poseida Therapeutics's earnings and revenue compare to its market cap?
2RZ fundamental statistics
Market cap€219.38m
Earnings (TTM)-€103.13m
Revenue (TTM)€80.90m

2.8x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2RZ income statement (TTM)
RevenueUS$88.46m
Cost of RevenueUS$156.78m
Gross Profit-US$68.32m
Other ExpensesUS$44.46m
Earnings-US$112.77m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.16
Gross Margin-77.23%
Net Profit Margin-127.48%
Debt/Equity Ratio96.7%

How did 2RZ perform over the long term?

See historical performance and comparison